303- Malcarne VL, Fox RS, Mills SD, Gholizadeh S. Psychosocial aspects of systemic sclerosis.
Curr Opin Rheumatol. 2013;25:707–13. doi: 10.1097/01.bor.0000434666.47397.c2. - Thombs BD, van Lankveld W, Bassel M, et al. Psychological health and well-being in sys-
temic sclerosis: state of the science and consensus research agenda. Arthritis Care Res
(Hoboken). 2010;62:1181–9. doi: 10.1002/acr.20187. - Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in
systemic sclerosis: a patient perspective. J Rheumatol. 2007;34(8):1718–26. - Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis.
Arthritis Rheum. 1980;23:137–45. - Pope J. Measures of systemic sclerosis (scleroderma). Arthritis Care Res.
2011;63(S11):S98–111. doi: 10.1002/acr.20598. - Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index
and Scleroderma Health Assessment Questionnaire in Scleroderma Trials: an evaluation of
their measurement properties. Arthritis Rheum. 2005;53:256–62. - Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease
activity and functional status in patients with scleroderma and Raynaud’s phenomenon.
Arthritis Rheum. 2002;46:2410–20. - Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The disability
index of the health assessment questionnaire is a predictor and correlate of outcome in the
high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum.
2001;44(3):653–61. - Steen VD, Medsger Jr TA. The value of the Health Assessment Questionnaire and special
patient-generated scales to demonstrate change in systemic sclerosis patients over time.
Arthritis Rheum. 1997;40:1984–91. doi: 10.1002/art.1780401110. - Sultan N, Pope JE, Clements PJ, Scleroderma Trials Study Group. The health assessment
questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma:
results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Rheumatology (Oxford). 2004;43:472–8. - Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices
make a difference in the score of the health assessment questionnaire-disability index?
Analysis from a scleroderma clinical trial. J Rheumatol. 2008;35:466–8. - The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of
life. Health Policy. 1990;16:199–208. - Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med.
2001;33:337–43. - Gualtierotti R, Scalone L, Ingegnoli F, Cortesi P, Lubatti C, Zeni S, et al. Health related qual-
ity of life assessment in patients with systemic sclerosis. Reumatismo. 2010;62(3):210–4. - Muller H, Rehberger P, Gunther C, Schmitt J. Determinants of disability, quality of life and
depression in dermatological patients with systemic scleroderma. Br J Dermatol.
2011;166(2):343–53. doi: 10.1111/j.1365-2133.2011.10624.x. - Strickland G, Pauling J, Cavill C, McHugh N. Predictors of health-related quality of life and
fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools.
Clin Rheumatol. 2012;31:1215–22. doi: 10.1007/s10067-012-1997-1. - Kwakkenbos L, Fransen J, Vonk MC, Becker ES, Jeurissen M, van den Hoogen FH, van den
Ende CH. A comparison of the measurement properties and estimation of minimal important
differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosis. Clin
Exp Rheumatol. 2013;31(2 Suppl 76):50–6. - Hudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG, et al. Discordance
between patient and physician assessments of disease severity in systemic sclerosis.
J Rheumatol. 2010;37:2307–12. doi: 10.3899/jrheum.100354. - Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness
score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-
dose penicillamine trial. Arthritis Rheum. 2000;43:2445–54.
11 PROMs for Systemic Sclerosis (Scleroderma)